AUTL (Autolus Therapeutics) 5-Year EBITDA Growth Rate: 23.10% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AUTL Autolus Therapeutics PLC AUTL
68 GF Score
Price $2.32
GF Value $23.52
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is Autolus Therapeutics 5-Year EBITDA Growth Rate?

Autolus Therapeutics AUTL -1.28% 68 5-Year EBITDA Growth Rate is 23.10% as of Jun. 2026. GuruFocus rates AUTL with a GF Score™ of 68/100 and a GF Value™ of $23.52 (Possible Value Trap). The stock has 8 warning signs investors should review.

Autolus Therapeutics's EBITDA per Share for the three months ended in Jun. 2026 was $-0.15.

During the past 3 years, the average EBITDA Per Share Growth Rate was 13.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 23.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Autolus Therapeutics was 33.90% per year. The lowest was -45.80% per year. And the median was 13.60% per year.

Autolus Therapeutics  (NAS:AUTL) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Autolus Therapeutics 5-Year EBITDA Growth Rate Related Terms

AUTL vs ALT, RGNX, CTNM: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Autolus Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Autolus Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Autolus Therapeutics's 5-Year EBITDA Growth Rate falls into.


AUTL
68GF Score
Autolus Therapeutics PLC AUTL
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autolus Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 23.10% mean?
Autolus Therapeutics (AUTL) has a 5-Year EBITDA Growth Rate of 23.10% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Autolus Therapeutics and its competitors.
Is Autolus Therapeutics' 5-Year EBITDA Growth Rate too high?
Autolus Therapeutics' current 5-Year EBITDA Growth Rate is 23.10%. Overall, Autolus Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' 5-Year EBITDA Growth Rate compare to ALT and RGNX?
Autolus Therapeutics' 5-Year EBITDA Growth Rate of 23.10% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Autolus Therapeutics and its competitors. Autolus Therapeutics's current 5-Year EBITDA Growth Rate is 23.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (AUTL) is currently considered Possible Value Trap. The stock's GF Value™ is $23.52, compared to a current price of $2.32 — trading 90.1% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 23.10%. Autolus Therapeutics' overall GF Score™ is 68/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Autolus Therapeutics (AUTL), the current 5-Year EBITDA Growth Rate is 23.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Autolus Therapeutics (AUTL) Overvalued in 2026?

Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued. The current stock price of $2.32 is trading 90.1% below its estimated GF Value™ of $23.52. GuruFocus considers Autolus Therapeutics to be Possible Value Trap.

Key valuation signals for AUTL:

  • 5-Year EBITDA Growth Rate: 23.10%
  • GF Value™: $23.52 vs. price of $2.32 (90.1% below fair value)
  • GF Score™: 68/100 with 8 warning signs

No single metric tells the full story. See the AUTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Autolus Therapeutics Business Description

Other Exchanges 6A3A:Germany
Address 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score

Get the complete analysis for AUTL

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.32
Price
$23.52
GF Value